Pivotal Role of mTOR Signaling in Hepatocellular CarcinomaAugusto Villanueva, Josep M. Llovet, Derek Y. Chiang et al.|Gastroenterology|2008Cited by 729
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivoPippa Newell, Josep M. Llovet, Sara Toffanin et al.|Journal of Hepatology|2009Cited by 222
PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC MutationsX. Le, J. Wang, Satoru Kitazono et al.|Journal of Thoracic Oncology|2024Cited by 14
155. Tumor Necrosis In Vivo Caused by a Novel Combination of Sorafenib and Rapamycin: Targeting the RAS and Motor Pathways ION Hepatocellular CarcinomaPippa Newell, Josep M. Llovet, Augusto Villanueva et al.|Journal of Surgical Research|2008Cited by 0
Activation of Ras/MAPK and mTOR pathways in hepatocellular carcinoma: Tumor growth inhibition with Ras/mTOR pathway abrogation by a novel combination of Sorafenib and rapamycinPhilippa Newell, Josep M. Llovet, Augusto Villanueva et al.|Journal of the American College of Surgeons|2007Cited by 0